Muhammed DEMİR, Mehmet ÖZBEK, Adem AKTAN, Faruk ERTAŞ

Fibrinogen to Albumin Ratio Predicts Burden of Coronary Artery Disease in Patients with NSTEMI

Objective: Fibrinogen plasma level rises in the event of inflammatory cases. It is known that there is a powerful intercourse between fibrinogen level and plasma viscosity. Albumin plasma level dropes during the inflammatory cases. The aim of this work determine significance of fibrinogen albumin ratio (FAR) as a indicator emphases the burden of atherosclerosis. Method: The study included 83 patients diagnosed with non-ST-segment elevation myocardial infarction (NSTEMI) between January and September 2015. The definition of NSTEMI was made according to “Definition of Third Universal Myocardial Infarction” guidelines published on 2013 by European Society of Cardiology. Burden of atherosclerosis was evaluated by Syntax score (SS) and Gensini Score. Patients were seperated two groups as medium-high SS (n=23) and low SS (n=60). FAR levels were compared. Results: FAR was 80.71 ± 30.3 in low SS group and 120 ± 49.72 in the mid-high SS group respectively (p

Fibrinogen to Albumin Ratio Predicts Burden of Coronary Artery Disease in Patients with NSTEMI

Keywords:

Fibrinogen, albumin, syntax score,

PDF

___

1. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 1999; 340: 115-26.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-95.
3. Kristensen SD. The platelet-vessel wall interaction in experimental atherosclerosis and ischaemic heart disease with special reference to thrombopoiesis. Dan Med Bull. 1992; 39: 110-27.
4. Serruys PW, Onuma Y, Garg S, et al. Assessment of the SYNTAX score in the syntax study. EuroIntervention. 2009; 5: 50–6.
5. Wykrzykowska JJ, Garg S, Girasis C, et al. Value of the SYNTAX score for risk assessment in the allcomers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. J Am Coll Cardiol. 2010; 56: 272–7.
6. Girasis C, Garg S, Raber L, et al. SYNTAX score and clinical SYNTAX score as predictors of very longterm clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimuseluting stent compared with pacliTAXeleluting stent for coronary revascularization (SIRTAX) trial. Eur Heart J. 2011; 32: 115–27.
7. Acet H, Ertaş F, Bilik M, et al. The relationship between neutrophil to lymphocyte ratio and SYNTAX score in patients with ST-segment elevation myocardial infarction. J Clin Exp Invest. 2014; 5: 211–8.
8. Tousoulis D, Papageorgiou N, Androulakis E, et al. Fibrinogen and cardiovascular disease, genetics and biomarkers. Blood Rev. 2011; 25: 239–45.
9. Reinhart WH. Fibrinogen marker or mediator of vascular disease? Vasc Med. 2003;8: 211–6.
10. Asayama K, Uchida N, Nakane T, et al. Antioxidants in the serum of children with insulindependent diabetes mellitus. Free Radical Bid Med. 1993; 15: 597-602.
11. Phillips A N, Shaper A G, Whincup P H. Association between serum albumin and mortality from cardiovascular disease, cancer and other causes. Lancer 1989; 1434-6.
12. Kuller L H, Eichner J E, Orchard T J, et al. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1991; 134: 1266- 77.
13. Gibson PH, Croal BL, Cuthbertson BH, et al. Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. Am Heart J. 2007;154: 995-1002.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
15. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-43.
16. Baetta R, Corsini A. Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis. 2010; 210: 1- 13.
17. Sullıvan DR, Marwick TH, Freedman SB, et al. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J. 1990; 119: 1262-66.
18. Mannucci PM. Recent progress in the pathophysiology of fibrinogen. Eur Heart J 1995; 16: 25–30.
19. Lowe GDO. Fibrinogen and cardiovascular disease: historical introduction. Eur Heart J. 1995; 16: 2–5.
20. Tataru MC, Schulte H, von Eckardstein A, et al. Plasma fibrinogen in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Coron Artery Dis. 2001; 12: 157-65.
21. Koichi H, Suminori K, Keijiro S, et al. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis. 1989; 77: 209-13.
22. Holm J, Ravn J, Ingemann Hansen S. Scand Jurol Nephrol. 2006; 40: 339-44
23. Felton CV, Crook D, Davies MJ, et al. Relation of Plaque Lipid Composition and Morphology to the Stability of Human Aortic Plaques. Arterioscler Thromb Vasc Biol. 1997; 17: 337–45.
24. Nobuhiko J, Hiroki H, Yuri T, et al. Relationship between serum albumin level before initiating haemodialysis and angiographic severity of coronary atherosclerosis in end-stage renal disease patients, Nephrol Dial Transplant. 2006; 21: 1633– 39
25. Ioannis L, Athanasios K, Georgios I, et al. Comparison of the extent and severity of coronary artery disease in patients with acute myocardial infarction with and without microAlbüminuria. The American Journal of Cardiology. 2004; 94: 334-37.
26. Parvizi R, Rahbani M, Salmasi SH, et al. Relationship between microalbüminuria and extent of coronary atherosclerotic lesions. Iran Heart J. 2005; 6: 20–5
27. Karahan O, Acet H, Ertaş F, et al. The relationship between fibrinogen to albumin ratio and severity of coronary artery disease in patients with STEMI. The American Journal of Emergency Medicine. 2016; 34: 1037-42.